{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:04:31Z","timestamp":1791072271254,"version":"4.1.0"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2001,9,1]],"date-time":"2001-09-01T00:00:00Z","timestamp":999302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2001,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The antibacterial activity of TAK-083 was tested against 54 clinical isolates of\n                    <jats:italic>Helicobacter pylori<\/jats:italic>\n                    and was compared with those of amoxicillin, clarithromycin, and metronidazole. The growth-inhibitory activity of TAK-083 was more potent than that of amoxicillin, clarithromycin, or metronidazole (the MICs at which 90% of the strains are inhibited were 0.031, 0.125, 64, and 8 \u03bcg\/ml, respectively). The antibacterial activity of TAK-083 was highly selective against\n                    <jats:italic>H. pylori<\/jats:italic>\n                    ; there was a &gt;30-fold difference between the concentration of TAK-083 required to inhibit the growth of\n                    <jats:italic>H. pylori<\/jats:italic>\n                    and that required to inhibit the growth of common aerobic and anaerobic bacteria. Exposure of\n                    <jats:italic>H. pylori<\/jats:italic>\n                    strains to TAK-083 at the MIC or at a greater concentration resulted in an extensive loss of viability. When four\n                    <jats:italic>H. pylori<\/jats:italic>\n                    strains were successively subcultured in the medium containing subinhibitory concentrations of TAK-083, no significant change in the MICs of this compound was observed. TAK-083 strongly inhibited the formation of tryptophanyl-tRNA in\n                    <jats:italic>H. pylori<\/jats:italic>\n                    while exhibiting little effect on the same system in eukaryotes. TAK-083 was efficacious in the treatment of gastric infection caused by\n                    <jats:italic>H. pylori<\/jats:italic>\n                    in Mongolian gerbils. The results presented here indicate that TAK-083 is a promising candidate for the treatment of\n                    <jats:italic>H. pylori<\/jats:italic>\n                    infection.\n                  <\/jats:p>","DOI":"10.1128\/aac.45.9.2455-2459.2001","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T06:06:42Z","timestamp":1027750002000},"page":"2455-2459","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":61,"title":["In Vitro and In Vivo Antibacterial Activities of TAK-083, an Agent for Treatment of\n                    <i>Helicobacter pylori<\/i>\n                    Infection"],"prefix":"10.1128","volume":"45","author":[{"given":"Tsuneo","family":"Kanamaru","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Pharmaceutical Discovery Research Laboratories IV, Pharmaceutical Discovery Research Division,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Nakano","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Pharmaceutical Discovery Research Laboratories IV, Pharmaceutical Discovery Research Division,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Toyoda","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Pharmaceutical Discovery Research Laboratories IV, Pharmaceutical Discovery Research Division,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Ichiro","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Pharmaceutical Discovery Research Laboratories IV, Pharmaceutical Discovery Research Division,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Tada","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Pharmaceutical Research Laboratories II, Pharmaceutical Research Division,2 Takeda Chemical Industries, Ltd., Osaka 532-8686, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Kaisho","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Pharmaceutical Research Laboratories II, Pharmaceutical Research Division,2 Takeda Chemical Industries, Ltd., Osaka 532-8686, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Nakao","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Pharmaceutical Research Laboratories II, Pharmaceutical Research Division,2 Takeda Chemical Industries, Ltd., Osaka 532-8686, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/00365528809091721","article-title":"The role of antibiotics in Campylobacter pylori associated peptic ulcer disease.","volume":"23","author":"Bayerdorfer E.","year":"1988","unstructured":"Bayerdorfer E. Ottenjann R. The role of antibiotics in Campylobacter pylori associated peptic ulcer disease. Scand. J. Gastroenterol. 23 1988 93 100","journal-title":"Scand. J. Gastroenterol."},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00042737-199409000-00004","article-title":"Short-term low dose triple therapy for the eradication of Helicobacter pylori.","volume":"6","author":"Bazzoli F.","year":"1994","unstructured":"Bazzoli F. Zagari R. M. Fossi S. Pozzato P. Alampi G. Simoni P. Sottili S. Ronda A. Ronda E. Short-term low dose triple therapy for the eradication of Helicobacter pylori. Eur. J. Gastroenterol. 6 1994 773 777","journal-title":"Eur. J. Gastroenterol."},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.2.248-254.2000"},{"key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF01962615","article-title":"Evaluation of a new selective medium for Campylobacter pylori.","volume":"7","author":"Dent J. C.","year":"1988","unstructured":"Dent J. C. McNulty C. A. M. Evaluation of a new selective medium for Campylobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 7 1988 555 558","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/35006081"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(87)90527-7","article-title":"Treatment failure of ofloxacin in Campylobacter pylori infection.","author":"Glupczynski Y.","year":"1987","unstructured":"Glupczynski Y. Labbe M. Burette A. Delmee M. Avesani V. Bruck C. Treatment failure of ofloxacin in Campylobacter pylori infection. Lancet i 1987 1096","journal-title":"Lancet"},{"key":"e_1_3_1_8_2","first-page":"1545","article-title":"Drug therapy for Helicobacter pylori infection: problems and pitfalls.","volume":"85","author":"Glupczynski Y.","year":"1990","unstructured":"Glupczynski Y. Burette A. Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am. J. Gastroenterol. 85 1990 1545 1551","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_3_1_9_2","first-page":"1552","article-title":"The who's and when's of therapy for Helicobacter pylori.","volume":"85","author":"Graham D. Y.","year":"1990","unstructured":"Graham D. Y. Borsch G. M. The who's and when's of therapy for Helicobacter pylori. Am. J. Gastroenterol. 85 1990 1552 1555","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0016-5085(92)90095-G","article-title":"Factors influencing the eradication of Helicobacter pylori with triple therapy.","volume":"102","author":"Graham D. Y.","year":"1992","unstructured":"Graham D. Y. Lew G. M. Malaty H. M. Evans D. J. Klein P. D. Alpert L. C. Genta R. M. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102 1992 493 496","journal-title":"Gastroenterology"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJM199302043280512","article-title":"Treatment of peptic ulcers caused by Helicobacter pylori.","volume":"328","author":"Graham D. Y.","year":"1993","unstructured":"Graham D. Y. Treatment of peptic ulcers caused by Helicobacter pylori. N. Engl. J. Med. 328 1993 349 350","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/BF01963775","article-title":"Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents.","volume":"8","author":"Grayson M. L.","year":"1989","unstructured":"Grayson M. L. Eliopoulos G. M. Ferraro M. J. Moellering R. C. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 8 1989 888 889","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91460-5"},{"key":"e_1_3_1_14_2","unstructured":"Kanamaru T. M. Nakao H. Tawada and K. Kamiyama. December 1997. Oxazolone derivatives and their use. Patent international publication no. WO97\/49703."},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/A:1026685929992","article-title":"Healing of Helicobacter pylori-induced gastric ulcers in Mongolian gerbils: combined treatment with omeprazole and clarithromycin.","volume":"44","author":"Keto Y.","year":"1999","unstructured":"Keto Y. Takahashi S. Okabe S. Healing of Helicobacter pylori-induced gastric ulcers in Mongolian gerbils: combined treatment with omeprazole and clarithromycin. Dig. Dis. Sci. 44 1999 257 265","journal-title":"Dig. Dis. Sci."},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/gut.34.9.1167","article-title":"Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, controlled study.","volume":"34","author":"Labenz J.","year":"1993","unstructured":"Labenz J. Gyenes E. Ruhl G. H. Borsch G. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, controlled study. Gut 34 1993 1167 1170","journal-title":"Gut"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/gut.35.1.19","article-title":"Evidence of the essential role of Helicobacter pylori in gastric ulcer disease.","volume":"35","author":"Labenz J.","year":"1994","unstructured":"Labenz J. Borsch G. Evidence of the essential role of Helicobacter pylori in gastric ulcer disease. Gut 35 1994 19 22","journal-title":"Gut"},{"key":"e_1_3_1_18_2","first-page":"A91","article-title":"Triple therapy using proton pump inhibitor-amoxicillin and clarithromycin for Helicobacter pylori eradication.","volume":"37","author":"Lamouliatte H.","year":"1995","unstructured":"Lamouliatte H. Cayla R. Zerbib F. Talbi P. M\u00e9graud F. Triple therapy using proton pump inhibitor-amoxicillin and clarithromycin for Helicobacter pylori eradication. Gut 37 (Suppl. 1) 1995 A91 (Abstract.)","journal-title":"Gut"},{"key":"e_1_3_1_19_2","first-page":"316","article-title":"PA155A, B and X: antibiotics produced by a strain of Streptomyces albus.","volume":"10","author":"Marsh W. S.","year":"1960","unstructured":"Marsh W. S. Garretson A. L. Wesel E. M. PA155A, B and X: antibiotics produced by a strain of Streptomyces albus. Antibiot. Chemother. 10 1960 316 320","journal-title":"Antibiot. Chemother."},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(88)90929-4","article-title":"Prospective, double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori.","author":"Marshall B. J.","year":"1988","unstructured":"Marshall B. J. Goodwin C. S. Warren J. R. Murray R. Blincow C. R. Prospective, double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet ii 1988 1437 1442","journal-title":"Lancet"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/bmj.293.6548.645","article-title":"Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate.","volume":"293","author":"McNulty C. A. M.","year":"1986","unstructured":"McNulty C. A. M. Gearty J. C. Crump B. Davis M. Donovan I. A. Melikian V. Lister D. M. Wise R. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br. Med. J. 293 1986 645 649","journal-title":"Br. Med. J."},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.10.2492"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-12-199406150-00001"},{"key":"e_1_3_1_24_2","unstructured":"Penner\n              J. L. Campylobacter Helicobacter and related spiral bacteria\n          Manual of clinical microbiology.\n              Balows\n              A.\n              Hausler\n              W. J.\n              Herrmann\n              K. L.\n              Isenberg\n              H. D.\n              Shadomy\n              H. J.\n          1991\n          402\n          409\n          American Society for Microbiology\n          Washington D.C."},{"key":"e_1_3_1_25_2","first-page":"1860","article-title":"Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial.","volume":"88","author":"Peterson W. L.","year":"1993","unstructured":"Peterson W. L. Graham D. Y. Marshall B. Blaser M. J. Genta R. M. Klein P. D. Stratton C. W. Drnec J. Prokocimer P. Siepman N. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am. J. Gastroenterol. 88 1993 1860 1864","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_3_1_26_2","first-page":"312","article-title":"PA155A: new antibiotic.","volume":"10","author":"Ras K. V.","year":"1960","unstructured":"Ras K. V. PA155A: new antibiotic. Antibiot. Chemother. 10 1960 312 315","journal-title":"Antibiot. Chemother."},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.1.163"},{"key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/00365529309098333","article-title":"Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer.","volume":"28","author":"Sipponen P.","year":"1993","unstructured":"Sipponen P. Hyvarinen H. Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scand. J. Gastroenterol. 28 (Suppl. 196) 1993 3 6","journal-title":"Scand. J. Gastroenterol."},{"key":"e_1_3_1_29_2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/jac\/22.1.92","article-title":"Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach.","volume":"22","author":"Stone J. W.","year":"1988","unstructured":"Stone J. W. Wise R. Donovan I. A. Gearty J. Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach. J. Antimicrob. Chemother. 22 1988 92 93","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199501193320302"},{"key":"e_1_3_1_31_2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0950-3528(95)90049-7","article-title":"Helicobacter pylori as a risk factor for cancer.","volume":"9","author":"Webb P. M.","year":"1995","unstructured":"Webb P. M. Forman D. Helicobacter pylori as a risk factor for cancer. Bailliere's Clin. Gastroenterol. 9 1995 563 582","journal-title":"Bailliere's Clin. Gastroenterol."},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1432-1033.1976.tb10758.x","article-title":"Indolmycin inhibits prokaryotic tryptophanyl-tRNA ligase.","volume":"68","author":"Werner R. G.","year":"1976","unstructured":"Werner R. G. Thorpe L. F. Reuter W. Nierhaus K. H. Indolmycin inhibits prokaryotic tryptophanyl-tRNA ligase. Eur. J. Biochem. 68 1976 1 3","journal-title":"Eur. J. Biochem."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.9.2455-2459.2001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.9.2455-2459.2001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T12:06:11Z","timestamp":1645445171000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.45.9.2455-2459.2001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2001,9]]}},"alternative-id":["10.1128\/AAC.45.9.2455-2459.2001"],"URL":"https:\/\/doi.org\/10.1128\/aac.45.9.2455-2459.2001","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9]]},"assertion":[{"value":"2001-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-06-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}